The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 07, 2015

Filed:

Apr. 02, 2012
Applicants:

David A. Scheinberg, New York, NY (US);

Tao Dao, New York, NY (US);

Cheng Liu, Oakland, CA (US);

Su Yan, State College, PA (US);

Inventors:

David A. Scheinberg, New York, NY (US);

Tao Dao, New York, NY (US);

Cheng Liu, Oakland, CA (US);

Su Yan, State College, PA (US);

Assignees:

MEMORIAL SLOAN KETTERING CANCER CENTER, New York, NY (US);

EUREKA THERAPEUTICS, INC., Emeryville, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/30 (2006.01); C07K 16/32 (2006.01); A61K 47/48 (2006.01); C07K 16/28 (2006.01); G01N 33/574 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/32 (2013.01); A61K 47/48561 (2013.01); A61K 2039/505 (2013.01); C07K 16/2833 (2013.01); C07K 2317/21 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); G01N 33/5748 (2013.01);
Abstract

The present invention provides antigen binding proteins that specifically bind to Wilms' tumor protein (WT1), including humanized, chimeric and fully human antibodies against WT1, antibody fragments, chimeric antigen receptors (CARs), fusion proteins, and conjugates thereof. The antigen binding proteins and antibodies bind to HLA-A0201-restricted WT1 peptide. Such antibodies, fragments, fusion proteins and conjugates thereof are useful for the treatment of WT1 associated cancers, including for example, breast cancer, ovarian cancer, prostate cancer, chronic myelocytic leukemia, multiple myeloma, acute lymphoblastic leukemia (ALL), acute myeloid/myelogenous leukemia (AML) and myelodysplastic syndrome (MDS). In more particular embodiments, the anti-WT1/A antibodies may comprise one or more framework region amino acid substitutions designed to improve protein stability, antibody binding and/or expression levels.


Find Patent Forward Citations

Loading…